Substance Abuse Clinical Trial
Official title:
A Single-site, Randomized, Double-blind, Double-dummy, Active-comparator, Placebo-controlled, 3-way Crossover Trial in Adult Non-dependent Recreational Opioid Users to Compare the Intranasal Abuse Potential of Immediate Release Abuse-deterrent and Standard Formulations of Oxycodone
The trial comprises an Enrollment Visit, a Qualification Phase, a Treatment Phase (including
3 treatment periods), a Final Examination, and a Follow-up Phone Call.
The Qualification Phase includes a naloxone challenge test (to verify that participants are
not opioid-dependent) and a drug discrimination test (to determine whether or not
participants are able to distinguish intranasally administered active drug from placebo).
Participants will be randomized to receive a single intranasal dose each of oxycodone active
pharmaceutical ingredient (API) and matching placebo in a double-blind manner. The total mass
of each single dose will be 30 milligrams.
Participants who successfully complete the Qualification Phase are eligible to be included in
the Treatment Phase. During the Treatment Phase, participants will receive test product,
comparator, and placebo following a randomized, double-blind, double-dummy, 3-way crossover
design. Participants will receive a single intranasal dose of each of the treatments
(combined doses of investigational medicinal product {IMP}) on Day 1, Day 4, and Day 7 of the
Treatment Phase. A single dose of a treatment is defined as insufflation of single doses of
the 2 applicable IMPs in quick succession. The 2 applicable IMPs must be insufflated in the
following pre-defined order. Oxycodone API or placebo to match oxycodone API must always be
insufflated first. Oxycodone immediate release (IR) abuse-deterrent formulation (ADF) or
placebo to match oxycodone IR ADF must always be insufflated second. The total mass of each
single dose of treatment will be 570 milligrams.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04070521 -
EEG Monitoring in the Emergency Department
|
||
| Completed |
NCT00729391 -
Women-Focused HIV Prevention in the Western Cape
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT03129334 -
Preventing Prescription Drug Abuse in Middle School Students
|
N/A | |
| Completed |
NCT02733003 -
Implementation Research for Vulnerable Women in South Africa
|
N/A | |
| Completed |
NCT02282306 -
Phone Interview to Prevent Recurring Opioid Overdoses
|
N/A | |
| Completed |
NCT02573948 -
Feasibility of Interventions on People Who Inject Drugs in Vietnam
|
||
| Withdrawn |
NCT01523444 -
Advancing Adolescent Screening and Brief Intervention Protocols in Primary Care Settings
|
Phase 3 | |
| Withdrawn |
NCT01847300 -
cSBI-M for Young Military Personnel
|
N/A | |
| Completed |
NCT01481428 -
Reducing High Risk Behavior in Treatment Court
|
Phase 1 | |
| Completed |
NCT01601743 -
Exercise as a Behavioral Treatment for Cocaine Dependence
|
N/A | |
| Completed |
NCT01591239 -
Home-Based Program to Help Parents of Drug Abusing Adolescents
|
N/A | |
| Active, not recruiting |
NCT00847548 -
Treatment of Intimate Partner Violence and Substance Abuse in a Forensic Setting
|
N/A | |
| Withdrawn |
NCT01228890 -
Primary Care Internet-Based Depression Prevention for Adolescents (CATCH-IT)
|
Phase 3 | |
| Completed |
NCT01614015 -
Building Outcomes With Observation-Based Supervision: An FFT Effectiveness Trial
|
Phase 2 | |
| Completed |
NCT01621334 -
The Men's Domestic Abuse Check-Up Engages Adult Men Concerned About Their Abusive Behavior and Alcohol or Drug Use
|
Phase 1 | |
| Completed |
NCT00717444 -
Healthy Activities for Prize Incentives
|
N/A | |
| Completed |
NCT00841711 -
Transitions: Linkages From Jail To Community
|
N/A | |
| Completed |
NCT01465490 -
Monitoring and Feedback in Substance Abuse Treatment
|
Phase 1/Phase 2 | |
| Completed |
NCT01188434 -
Integrating Interventions for Maternal Substance Abuse
|
Phase 1 | |
| Completed |
NCT00685074 -
Computer-based Brief Intervention for Perinatal Substance Abuse
|
Phase 1/Phase 2 |